|
[1]
|
Kong, P., Cui, Z.-Y., Huang, X.-F., et al. (2022) Inflammation and Atherosclerosis: Signaling Pathways and Therapeutic Intervention. Signal Transduction and Targeted Therapy, 7, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Everett, B.M. (2019) Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular Events. Journal of the American College of Cardiology, 73, 2410-2412. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ridker, P.M. (2018) Clinician’s Guide to Reducing In-flammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Journal of the American College of Cardiology, 72, 3320-3331. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Walsh, C.P., Lindsay, E.K., Grosse, P., et al. (2023) A Systematic Review and Meta-Analysis of the Stability of Peripheral Immune Markers in Healthy Adults. Brain, Behavior, and Im-munity, 107, 32-46. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wong, N.D., Budoff, M.J., Ferdinand, K., et al. (2022) Atheroscle-rotic Cardiovascular Disease Risk Assessment: An American Society for Preventive Cardiology Clinical Practice State-ment. American Journal of Preventive Cardiology, 10, Article 100335. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Takahashi, M. (2022) NLRP3 Inflammasome as a Key Driver of Vascular Disease. Cardiovascular Research, 118, 372-385. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Abbate, A., Toldo, S., Marchetti, C., et al. (2020) Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Dis-ease. Circulation Research, 126, 1260-1280. [Google Scholar] [CrossRef]
|
|
[8]
|
Ridker, P.M., Bhatt, D.L., Pradhan, A.D., et al. (2023) Inflammation and Cholesterol as Predictors of Cardiovascular Events among Patients Receiving Statin Therapy: A Collaborative Analysis of Three Randomised Trials. The Lancet, 401, 1293-1301. [Google Scholar] [CrossRef]
|
|
[9]
|
Takahashi, N., Dohi, T., Endo, H., et al. (2020) Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 9, Article 1033. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Klingenberg, R., Aghlmandi, S., Gencer, B., et al. (2021) Residual In-flammatory Risk at 12 Months after Acute Coronary Syndromes Is Frequent and Associated with Combined Adverse Events. Atherosclerosis, 320, 31-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Van’t Klooster, C.C., Van Der Graaf, Y., Ridker, P.M., et al. (2020) The Relation between Healthy Lifestyle Changes and Decrease in Systemic Inflammation in Patients with Stable Cardiovascular Disease. Atherosclerosis, 301, 37-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Gao, K., Su, Z., Meng, J., et al. (2024) Effect of Exercise Training on Some Anti-Inflammatory Adipokines, High Sensitivity C-Reactive Protein, and Clinical Outcomes in Seden-tary Adults with Metabolic Syndrome. Biological Research for Nursing, 26, 125-138. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Bianchi, V.E. (2018) Weight Loss Is a Critical Factor to Reduce Inflammation. Clinical Nutrition ESPEN, 28, 21-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Barnard, N.D., Goldman, D.M., Loomis, J.F., et al. (2019) Plant-Based Diets for Cardiovascular Safety and Performance in Endurance Sports. Nutrients, 11, Article 130. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Jukema, R.A., Ahmed, T.A.N. and Tardif, J.C. (2019) Does Low-Density Lipoprotein Cholesterol Induce Inflammation? If So, Does It Matter? Current Insights and Future Perspec-tives for Novel Therapies. BMC Medicine, 17, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Amezcua-Castillo, E., González-Pacheco, H., Sáenz-San Martín, A., et al. (2023) C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Dis-ease—Advancing toward Precision Medicine. Biomedicines, 11, Article 2444. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Ruscica, M., Tokgözoğlu, L., Corsini, A., et al. (2019) PCSK9 Inhibition and Inflammation: A Narrative Review. Atherosclerosis, 288, 146-155. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Tardif, J.-C., Kouz, S., Waters, D.D., et al. (2019) Effi-cacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 381, 2497-2505. [Google Scholar] [CrossRef]
|
|
[19]
|
Nidorf, S.M., Fiolet, A.T.L., Mosterd, A., et al. (2020) Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 383, 1838-1847. [Google Scholar] [CrossRef]
|
|
[20]
|
Bao, Y.L., Gu, L.F., Du, C., et al. (2022) Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Phar-macology, 80, 639-647. [Google Scholar] [CrossRef]
|
|
[21]
|
Ajala, O.N. and Everett, B.M. (2020) Targeting Inflammation to Reduce Residual Cardiovascular Risk. Current Atherosclerosis Reports, 22, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Ku, E.J., Kim, B.R., Lee, J.I., et al. (2022) The An-ti-Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Apolipoprotein E Knockout Mice. International Journal of Molecular Sciences, 23, Article 4906. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Abbate, A., Wohlford, G.F., Del Buono, M.G., et al. (2022) Interleu-kin-1 Blockade with Anakinra and Heart Failure Following ST-Segment Elevation Myocardial Infarction: Results from a Pooled Analysis of the VCUART Clinical Trials. European Heart Journal-Cardiovascular Pharmacotherapy, 8, 503-510. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ridker, P.M., Everett, B.M., Thuren, T., et al. (2017) Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377, 1119-1131. [Google Scholar] [CrossRef]
|
|
[25]
|
Ridker, P.M., Libby, P., MacFadyen, J.G., et al. (2018) Modulation of the Interleukin-6 Signalling Pathway and Incidence Rates of Atherosclerotic Events and All-Cause Mortal-ity: Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal, 39, 3499-3507. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kleveland, O., Kunszt, G., Bratlie, M., et al. (2016) Effect of a Single Dose of the Interleukin-6 Receptor Antagonist to Cilizumab on Inflammation and Troponin T Release in Patients with Non-ST-Elevation Myocardial Infarction: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. European Heart Journal, 37, 2406-2413. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Broch, K., Anstensrud, A.K., Woxholt, S., et al. (2021) Randomized Trial of Interleukin-6 Receptor Inhibition in Patients WithAcute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 77, 1845-1855. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Ridker, P.M., Devalaraja, M., Baeres, F.M.M., et al. (2021) IL-6 Inhibition with Ziltivekimab in Patients at High Atherosclerotic Risk (RESCUE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet, 397, 2060-2069. [Google Scholar] [CrossRef]
|
|
[29]
|
Ridker, P.M. (2021) From RESCUE to ZEUS: Will Interleu-kin-6 Inhibition with Ziltivekimab Prove Effective for Cardiovascular Event Reduction? Cardiovascular Research, 117, e138-e140. [Google Scholar] [CrossRef] [PubMed]
|